Short answer
CRISPR Therapeutics AG (CRSP) filed an 8-K current report with the SEC on June 4, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 5.07 (Submission of Matters to a Vote of Security Holders). Shareholders approved the 2026 Stock Option and Incentive Plan on June 4, 2026.
CRISPR Therapeutics AG 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Shareholders approved the 2026 Stock Option and Incentive Plan on June 4, 2026
- New plan carries forward remaining 2018 Plan shares plus shares from forfeited or canceled awards
- Eligible awards include options, stock appreciation rights, restricted stock, performance awards and dividend equivalents
- Potential shareholder dilution depends on available shares and future equity awards
- Share pool adjusts for reorganizations, recapitalizations, stock splits and similar events
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Shareholders approved amended and restated Articles of Association at the June 4, 2026 Annual Meeting
- Amendments effective upon Zug Commercial Register registration, subject to Swiss Federal Commercial Authority approval
- Revised governing documents may affect shareholder rights and corporate governance provisions
- Full amended Articles of Association attached as Exhibit 3.1
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Shareholders approved 2025 financial statements, loss carryforward, director discharge, and all 11 board re-elections, preserving governance continuity
- Capital-band expansion and conditional share-capital increase approved, strengthening financing and potential convertible-debt flexibility
- 2026 Plan approved with 42,839,199 votes for, supporting continued equity-based compensation and potential dilution
- Executive equity compensation received the weakest binding support: 33,726,778 for versus 14,883,412 against
- Ernst & Young AG and Ernst & Young LLP re-elected as statutory and independent registered auditors for 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CRISPR Therapeutics AG 8-K filings
Get the next CRSP 8-K as it lands
Follow CRSP for push alerts, or ask the research agent what this filing means.